# Chemical Compounds to Block a Specific KRAS Cancer Gene > This patent describes new chemical compounds designed to stop a specific mutated protein called KRAS G12C, which is often found in various cancers, potentially offering new ways to treat the disease. - **Patent:** US 12735425 - **Original title:** 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of KRAS G12C mutant - **Granted:** 2026 - **Status:** Active - **Times cited:** 0 - **Field:** pharmaceutical, biotech, oncology, drug_discovery ## What it does This patent describes new chemical compounds, generally referred to as Formula (I), and their pharmaceutically acceptable salts. These compounds are designed to stop or 'inhibit' the activity of a specific mutated protein called KRAS G12C. By blocking this protein, the compounds are intended to act as therapeutic agents to treat various types of cancer. The patent also covers pharmaceutical compositions containing these compounds and methods for using them in the therapy and prophylaxis of cancer. For example, a patient with lung cancer driven by the KRAS G12C mutation could receive a drug based on these compounds to slow or stop tumor growth. Without the specific claims, the precise chemical structures and their exact scope of protection are not detailed. ## What it does NOT cover - Does not cover inhibitors for other specific KRAS mutations, such as KRAS G12D or KRAS G12V. - Does not cover cancer treatments that target different proteins or biological pathways unrelated to KRAS G12C. - Does not cover non-chemical methods of inhibiting KRAS G12C, such as gene editing or RNA interference. - Does not cover compounds that do not fall under the general chemical description of Formula (I) as implied by the abstract. - Does not cover treating cancers where the KRAS G12C mutation is not present. ## The clever bit The clever bit is identifying specific chemical structures (Formula I) that can selectively bind to and inhibit the KRAS G12C mutant protein. This is a significant challenge because KRAS is a small protein with a smooth surface, making it difficult for drugs to attach effectively. The compounds described here achieve this precise targeting. ## Real-world examples 1. Sotorasib (Lumakras) 2. Adagrasib (Krazati) 3. Targeted lung cancer therapies 4. Targeted colorectal cancer therapies ## Why it matters The KRAS G12C mutation is a common driver in several difficult-to-treat cancers, including lung, colorectal, and pancreatic cancers. For decades, KRAS was considered 'undruggable,' meaning scientists struggled to find ways to block its activity with medicines. This patent contributes to the development of specific chemical compounds that can overcome this challenge, offering a new class of targeted therapies for patients with these specific mutations. ## Frequently asked questions ### What does Chemical Compounds to Block a Specific KRAS Cancer Gene cover? This patent describes new chemical compounds designed to stop a specific mutated protein called KRAS G12C, which is often found in various cancers, potentially offering new ways to treat the disease. ### When does this patent expire? This patent is expected to expire on September 15, 2046, when the invention enters the public domain. ### What problem does this patent solve? The KRAS G12C mutation is a common driver in several difficult-to-treat cancers, including lung, colorectal, and pancreatic cancers. For decades, KRAS was considered 'undruggable,' meaning scientists struggled to find ways to block its activity with medicines. This patent contributes to the development of specific chemical compounds that can overcome this challenge, offering a new class of targeted therapies for patients with these specific mutations. ### What does this patent NOT cover? Does not cover inhibitors for other specific KRAS mutations, such as KRAS G12D or KRAS G12V. **Full plain-English explainer:** https://patentbrief.org/patent/us/12735425/67-dihydro-pyrano23-dpyrimidine-inhibitors-of-kras-g12c-mutant **Original patent:** https://patents.google.com/patent/US12735425 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [New Pyrimidine Chemical Compounds for Treating Tumors](https://patentbrief.org/patent/us/5521184/gleevec-imatinib) — This patent describes specific new chemical compounds, called N-phenyl-2-pyrimidine-amine derivatives, designed with precise molecular structures for potential use in treating cancer. - [How Ibrutinib-like Molecules Block Cancer-Causing Proteins](https://patentbrief.org/patent/us/8957079/pomalyst-pomalidomide) — A chemical design for molecules that permanently latch onto and disable a specific protein called Btk, which is often responsible for the growth of certain blood cancers. - [How to Manufacture a Complex Cancer-Fighting Drug Molecule](https://patentbrief.org/patent/us/12365678/raptor-production) — A detailed chemical recipe for mass-producing a specific cancer-fighting molecule, including the intermediate building blocks needed to construct it efficiently. - [Using Two Specific RNAs to Teach the Body to Fight Lung Cancer](https://patentbrief.org/patent/us/20220096616/composition-for-treating-lung-cancer-particularly-of-non-small-lung-cancers-nscl) — This patent describes an active composition containing two specific messenger RNAs, NY-ESO-1 and MAGE-A3, designed to stimulate an immune response in a mammal to treat lung cancer, especially non-small cell lung cancers. - [Using Antibodies to Block HER3 Proteins in Cancer Cells](https://patentbrief.org/patent/us/9011851/perjeta-pertuzumab) — A patent describing specific antibodies that bind to and block the HER3 protein, which is often used by cancer cells to grow and survive.